Efficacy Study of Olmesartan Medoxomil on Coronary Atherosclerosis and Epicardial Adipose Tissue(EAT)

• Status: Unknown status
• Trial end date: 2016-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether olmesartan medoxomil is effective in the treatment of coronary atherosclerosis progression and epicardial adipose tissue(EAT) volume reduction in patients with coronary atherosclerosis detected by coronary CT angiography(CCTA).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chinese PLA General Hospital
• Treatments: Antihypertensive Agents; Calcium Channel Blockers; Olmesartan; Olmesartan Medoxomil

Criteria

Inclusion Criteria:

• coronary artery stenosis between 30% and 70% determined by CCTA in essential hypertension patients

• resting diastolic blood pressure (DBP) between 90 and 110 mmHg

• type A and B for coronary artery vascular lesions

Exclusion Criteria:

• secondary hypertension

• coronary artery stenosis less than 30% or greater than 70% determined by CCTA

• contraindications to treatment with olmesartan medoxomil (allergy, glaucoma, digestive ulcer, is currently taking phosphodiesterase-5 inhibitor)

• resting systolic blood pressure (SBP) > 200 mmHg or resting diastolic blood pressure (DBP) > 110 mmHg

• Severe calcification, distortion or type C for coronary artery vascular lesions

• pregnancy

• unwillingness or inability to provide informed consent